参考文献/References:
[1] Müller HL,Merchant TE,Warmuth-Metz M,et al.Craniopharyngioma[J].Nat Rev Dis Primers,2019,5(1):75.DOI:10.1038/s41572-019-0125-9.
[2] Wu W,Sun Q,Zhu X,et al.Risk factors for hypothalamic obesity in patients with adult-onset craniopharyngioma:a consecutive series of 120 cases[J].Front Endocrinol(Lausanne),2021,12(undefined):694213.DOI:10.3389/fendo.2021.694213.
[3] Niel KA,Klages KL,Merchant TE,et al.Impact of sleep,neuroendocrine,and executive function on health-related quality of life in young people with craniopharyngioma[J].Dev Med Child Neurol,2021,63(8):984-990.DOI:10.1111/dmcn.14866.
[4] Giese H,Haenig B,Haenig A,et al.Neurological and neuropsychological outcome after resection of craniopharyngiomas[J].J Neurosurg,2019,132(5):1425-1434.DOI:10.3171/2018.10.JNS181557.
[5] Higham CE,Johannsson G,Shalet SM.Hypopituitarism[J].Lancet,2016,388(10058):2403-2415.DOI:10.1016/S0140-6736(16)30053-8.
[6] Fleseriu M,Hashim IA,Karavitaki N,et al.Hormonal Replacement in Hypopituitarism in Adults:An Endocrine Society Clinical Practice Guideline[J].J Clin Endocrinol Metab,2016,101(11):3888-3921.DOI:10.1210/jc.2016-2118.
[7] Boguszewski MCS,Boguszewski CL,Chemaitilly W,et al.Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours:a consensus statement[J].Eur J Endocrinol,2022,186(6): P35-P52.DOI:10.1530/EJE-21-1186.
[8] Boekhoff S,Bogusz A,Sterkenburg AS,et al.Long-term effects of growth hormone replacement therapy in childhood-onset craniopharyngioma:results of the German craniopharyngioma registry(HIT-Endo)[J].Eur J Endocrinol,2018,179(5):331-341.DOI:10.1530/EJE-18-0505.
[9] Yuen KCJ,Biller BMK,Radovick S,et al.American Association Of Clinical Endocrinologists And American College Of Endocrinology Guidelines For Management Of Growth Hormone Deficiency In Adults And Patients Transitioning From Pediatric To Adult Care[J].Endocr Pract,2019,25(11):1191-1232.DOI:10.4158/GL-2019-0405.
[10] 中华医学会内分泌学分会.成人生长激素缺乏症诊治专家共识(2020版)[J].中华内分泌代谢杂志,2020,36(12):995-1002.DOI:10.3760/cma.j.cn311282-20201130-00798.
[11] 中华医学会儿科学分会内分泌遗传代谢学组,中华儿科杂志编辑委员会.过渡期生长激素缺乏症诊断及治疗专家共识[J].中华儿科杂志,2020,58(6):455-460.DOI:10.3760/cma.j.cn112140-20200314-00237.
[12] Li X,Wu W,Miao Q,et al.Endocrine and metabolic outcomes after transcranial and endoscopic endonasal approaches for primary resection of craniopharyngiomas[J].World Neurosurg,2019,121:e8-e14.DOI:10.1016/j.wneu.2018.08.092.
[13] Sarkar S,Korula S,Mathai S,et al.Upfront adjuvant irradiation versus postoperative surveillance following incomplete surgical resection of craniopharyngiomas in children and young adults[J].Childs Nerv Syst,2022,38(10):1877-1883.DOI:10.1007/s00381-022-05635-z.
[14] Wu J,Fu J,Huang ZJ,et al.Postoperative hypothalamic damage predicts postoperative weight gain in patients with adult-onset craniopharyngioma[J].Obesity(Silver Spring),2022,30(7):1357-1369.DOI:10.1002/oby.23447.
[15] Shoemaker AH,Tamaroff J.Approach to the patient with hypothalamic obesity[J].J Clin Endocrinol Metab,2023,108(5):1236-1242.DOI:10.1210/clinem/dgac678.
[16] Tamhane S,Sfeir JG,Kittah NEN,et al.GH therapy in childhood cancer survivors:a systematic review and meta-analysis[J].J Clin Endocrinol Metab,2018,103(8):2794-2801.DOI:10.1210/jc.2018-01205.
[17] Roth CL,Perez FA,Whitlock KB,et al.A phase 3 randomized clinical trial using a once-weekly glucagon-like peptide-1 receptor agonist in adolescents and young adults with hypothalamic obesity[J].Diabetes Obes Metab,2021,23(2):363-373.DOI:10.1111/dom.14224.
[18] Shoemaker AH,Silver HJ,Buchowski M,et al.Energy balance in hypothalamic obesity in response to treatment with a once-weekly GLP-1 receptor agonist[J].Int J Obes(Lond),2022,46(3):623-629.DOI:10.1038/s41366-021-01043-6.
[19] Clément K,van den Akker E,Argente J,et al.Efficacy and safety of setmelanotide,an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency:single-arm, open-label, multicentre, phase 3 trials[J].Lancet Diabetes Endocrinol,2020,8(12):960-970.DOI:10.1016/S2213-8587(20)30364-8.
[20] Haqq AM,Chung WK,Dollfus H,et al.Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome:a multicentre,randomised,double-blind,placebo-controlled,phase 3 trial with an open-label period[J].Lancet Diabetes Endocrinol,2022,10(12):859-868.DOI:10.1016/S2213-8587(22)00277-7.
[21] 吴蔚,杨叶虹,李益明.下丘脑性肥胖临床研究进展[J].国际内分泌代谢杂志,2014,34(1):32-35.DOI:10.3760/cma.j.issn.1673-4157.2014.01.009.
[22] Wijnen M,Olsson DS,van den Heuvel-Eibrink MM,et al.Efficacy and safetyof bariatric surgery for craniopharyngioma-related hypothalamic obesity:a matched case-control study with 2 years of follow-up[J].Int J Obes(Lond),2017,41(2):210-216.DOI:10.1038/ijo.2016.195.
[23] van Iersel L,Brokke KE,Adan RAH,et al.Pathophysiology and individualized treatment of hypothalamic obesity following craniopharyngioma and other suprasellar tumors:a systematic review[J].Endocr Rev,2019,40(1):193-235.DOI:10.1210/er.2018-00017.